Impact of Sarcopenia in Healthy Aging and Suggested Interventions
Sarcopenia is a condition characterized by loss of skeletal muscle mass and function with aging and is associated with frailty, physical disability, falls, and higher mortality.
Many factors play role in the pathophysiology of sarcopenia. These include genetic factors, mitochondrial defects, decreased anabolic hormones, inflammatory cytokines, insulin resistance, decreased protein intake and activity, poor blood flow to muscle, and growth-derived factor-11 deficiency. The molecular mechanisms underlying and/or associated with sarcopenia have significant role in aging. Hence, interventions targeting sarcopenia shall have an impact on healthy aging. At present, the best-demonstrated and practically recommended approaches to prevent/treat sarcopenia are resistance exercises and intake of adequate protein and vitamin D. Adequate intake of protein and resistance exercises are mandatory to preserve muscle mass. Many other promising treatment modalities are currently being investigated listed on the way.
KeywordsAging Intervention Molecular mechanisms Sarcopenia
- Dalton JT, Barnette KG, Bohl CE et al (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachex Sarcopenia Muscle 2:153–161CrossRefGoogle Scholar
- Farooqi V, van den Berg ME, Cameron ID et al (2014) Anabolic steroids for rehabilitation after hip fracture in older people. Cochrane Database Syst Rev 10:CD008887Google Scholar
- Karakelides H, Nair KS (2005) Sarcopenia of aging and its metabolic impact. Curr Top Dev Biol 68:123e148Google Scholar
- Koopman R, Verdijk LB, Van Loon LJC (2010) Exercise and nutritional interventions to combat age-related muscle loss sarcopenia – age-related muscle wasting and weakness. pp 289–315Google Scholar
- Malik F, Hwee D, Kennedy A et al (2014) Fast skeletal muscle troponin activator Tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. Neurology 82(10 Supplement):1.081Google Scholar
- Steward Coats AJ, Srinivasan Surendran J, Chicarmana H et al (2011) The ACT-ONE trial, a multicenter, randomized, double-blind, placebo-controlled dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2:201–207CrossRefGoogle Scholar